Trial Search Results
International Collaborative Gaucher Group (ICGG) Gaucher Registry
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
- To enhance the understanding of the variability, progression, and natural history of Gaucher disease with the ultimate goal of better guiding and assessing therapeutic interventions;
- To provide the Gaucher medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and
- To evaluate the long-term effectiveness of Cerezyme.
Stanford is currently accepting patients for this trial.
Genzyme, a Sanofi Company
- All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion
in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase
deficiency and/or mutation in the β-glucocerebrosidase gene.
- For all patients, appropriate patient authorization will be obtained.
- No exclusion criteria for participation in the ICGG Gaucher Registry.NOTE: Registry
participation does not exclude participation in other clinical studies.
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study